SCHEMBL6299259

SCHEMBL6299259

CCCc1ccc(C(=O)OC)cc1N

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.58
ALDH1A1 P00352 7/20 0.58
MAPT P10636 7/20 0.58
HPGD P15428 6/20 0.58
GAA P10253 3/20 0.58
HSD17B10 Q99714 3/20 0.58
ATM Q13315 2/20 0.58
GLA P06280 1/20 0.58
CASP1 P29466 1/20 0.58
CASP7 P55210 1/20 0.58
ERAP2 Q6P179 3/20 0.50
LNPEP Q9UIQ6 3/20 0.50
USP2 O75604 1/20 0.50
PPARG P37231 2/20 0.48
PPARA Q07869 2/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12693538 0.90 KDM4E (0.66) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL7997079 0.89 KDM4E (0.54) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL27202970 0.84 MAPT (0.55) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL28797567 0.84 ALDH1A1 (0.53) KDM4EALDH1A1MAPTHPGDNPC1
SCHEMBL12419937 0.83 PPARG (0.50) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL5455910 0.83 KDM4E (0.62) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL15862062 0.83 KDM4E (0.62) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL30211954 0.83 LOXL2 (0.51) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL13553385 0.82 PPARG (0.51) KDM4EALDH1A1MAPTHPGDGAA
SCHEMBL6179410 0.81 GAA (0.58) KDM4EALDH1A1MAPTHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109415553-B Plasticized thermoset resins and related cured resins, curing methods, and articles comprising cured resins 马萨诸塞大学 2022-08-05 CN claimed
EP-3481899-A1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN The University of Massachusetts (US) 2019-05-15 EP claimed
CN-109415553-A The thermosetting resin of plasticising and related solidified resin, curing method and the product comprising solidified resin 马萨诸塞大学 2019-03-01 CN claimed
WO-2018008003-A1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN THE UNIVERSITY OF MASSACHUSETTS (US) 2018-01-11 WO claimed
EP-3481899-B1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN UNIV MASSACHUSETTS (US) 2022-12-21 EP disclosed
CN-109415553-B Plasticized thermoset resins and related cured resins, curing methods, and articles comprising cured resins 马萨诸塞大学 2022-08-05 CN disclosed
US-10913844-B2 Plasticized thermoset resin, and associated cured resin, method of curing, and article comprising cured resin THE UNIVERSITY OF MASSACHUSETTS (US) 2021-02-09 US disclosed
US-20190309159-A1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN THE UNIVERSITY OF MASSACHUSETTS 2019-10-10 US disclosed
EP-3481899-A1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN The University of Massachusetts (US) 2019-05-15 EP disclosed
CN-109415553-A The thermosetting resin of plasticising and related solidified resin, curing method and the product comprising solidified resin 马萨诸塞大学 2019-03-01 CN disclosed
WO-2018008003-A1 PLASTICIZED THERMOSET RESIN, AND ASSOCIATED CURED RESIN, METHOD OF CURING, AND ARTICLE COMPRISING CURED RESIN THE UNIVERSITY OF MASSACHUSETTS (US) 2018-01-11 WO disclosed
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed
EP-0061907-A1 Secondary amines, their preparation, pharmaceutical compositions containing them and their use BEECHAM GROUP PLC (GB) 1982-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 KDM4E 1305/4885ALDH1A1 570/4885MAPT 4591/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM KDM4E 935/4885ALDH1A1 1067/4885MAPT 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.